Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
71. |
ECCT/12/09/03 | REALITY Trial Reduction of EArly mortaLITY in HIV-infected adults and children starting antiretroviral therapy |
Principal Investigator(s) 1. DR ANTHONY OLIWA ETYANG Site(s) in Kenya 1. KEMRI Wellcome Trust Research Programme (Kilifi county) 2. Moi University School of Medicine, Academic Model for the Prevention and Treatment of HIV/AIDS (AMPATH) Centre at Moi Teaching Referral Hospital (MTRH) (Uasin Gishu county) |
View |
72. |
ECCT/12/03/01 | Role of Fish Oil Omega-3 Fatty Acids on Depression among HIV-Seropositive Pregnant Women in Nairobi: A Randomized Double-blind Controlled Trial |
Principal Investigator(s) 1. Rose Okoyo Opiyo Site(s) in Kenya 1. Riruta Health Centre (Nairobi City county) 2. Kariobangi North Health Centre (Nairobi City county) 3. Mathare North Health Centre (Nairobi City county) 4. Kayole II Sub-district hospital (Nairobi City county) |
View |
73. |
ECCT/20/04/03 | 518 & 525-SHAN6™ Study Title: Safety and Immunogenicity Study of Full Schedule (3-Dose SHAN6™) or SHAN6™- SHAN 5®- SHAN6™ Versus the Licensed Vaccine SHAN 5® With bOPV and IPV When Administered Per National Immunization Schedule in Healthy Kenyan Infants. Phase III, multi-center, randomized, active-controlled, open-label, three-arm, study in 690 infants who will receive a 3-dose primary series at 6, 10 and 14 weeks of age, of either 3-dose SHAN6™ or SHAN6™ – SHAN 5® + bOPV – SHAN6™ or SHAN 5® + bOPV – SHAN 5® + bOPV – SHAN 5® + bOPV + IPV, and a booster dose of either SHAN6™ or SHAN 5® + bOPV at 18 months of age |
Principal Investigator(s) 1. Bernhards Ogutu 2. Godfrey Allan Otieno 3. Videlis Nduba 4. Lucy Chepkurui Koech 5. samuel Gurrion Ouma 6. Janet Oyieko Site(s) in Kenya 1. Ahero Clinical Trials Unit (Kisumu county) 2. KEMRI, Centre for Respiratory Diseases Research (CRDR) (Nairobi City county) 3. KEMRI Kondele Children’s Hospital (Kisumu county) 4. KEMRI / Walter Reed Project, Clinical Research Centre, Kericho (Kericho county) 5. KEMRI CGHR, CLINICAL RESEARCH CENTRE (Kisumu county) 6. KEMRI Centre forClinical Research(CCR)_Butere County Hospital (Kakamega county) 7. CRDR_Siaya Annex(Back-up site) (Siaya county) |
View |
74. |
ECCT/22/08/02 | AIM-LVRNA009-II_III-01 A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 2/3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) for the Prevention of COVID-19 in Participants Aged 18 Years and Olde |
Principal Investigator(s) 1. Bernhards Ogutu 2. Lucas Otieno 3. Videlis Nduba 4. Bernhards Ogutu 5. Jacqueline Mirera 6. Jacqueline Mirera Site(s) in Kenya 1. Siaya Clinical Trials Unit (Siaya county) 2. Homa Bay Clinical Trials Unit (Homa Bay county) 3. Ahero Clinical Trials Unit (Kisumu county) 4. CREA-N Machakos (Machakos county) 5. CREA-N Nakuru (Nakuru county) 6. Victoria Biomedical Research Institue (Kisumu county) |
View |
75. |
ECCT/21/03/01 | Recombinant COVID-19 vaccine A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells), for the prevention of COVID-19 in adults aged 18 years and older |
Principal Investigator(s) 1. Walter Jaoko Jaoko Site(s) in Kenya KAVI-institute of Clinical Research |
View |